Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19279668 | 0.86 | ADAMTS5 (0.53) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL27819269 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4ADAMTS5ALDH1A1SMN1; SMN2 | |
| SCHEMBL15206031 | 0.81 | CHRNB2 (0.55) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL15206038 | 0.81 | CHRNB2 (0.55) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL3325463 | 0.81 | IDO1 (0.42) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL11028141 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4ADAMTS5POLBHCAR2 | |
| SCHEMBL1704960 | 0.79 | GPR119 (0.51) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL6498731 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4ADAMTS5ALDH1A1MAPT | |
| SCHEMBL16935399 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2225363 | 0.78 | IDO1 (0.43) | ALDH1A1MAPTSMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| US-8470827-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| EP-2489663-A1 | Compounds as syk kinase inhibitors | Almirall, S.A. (ES) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7618970-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1763351-A4 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1763347-A4 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7449467-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | PFIZER INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1763351-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1763347-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-26 | — | — | US | disclosed |
| WO-2006004741-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004684-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CHRNB2 1563/4885CHRNA4 935/4885ADAMTS5 2935/4885 |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CHRNB2 1563/4885CHRNA4 935/4885ADAMTS5 2935/4885 |
| US-20100119503-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CHRNB2 1563/4885CHRNA4 935/4885ADAMTS5 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.